Top 10 Companies in Liquid Biopsy Detailed in New Report
ROCKVILLE, Md., July 18, 2017 /PRNewswire/ -- New York City-based healthcare market researcher Kalorama Information details the top 10 liquid biopsy companies and their activities in a new report. The market, Kalorama says, is heterogeneous and very fragmented, with many companies commercializing various liquid biopsy diagnostic products and developing new ones for a broad range of applications. But a few top competitors can be expected to stay in long-term. Roche, Qiagen, Biocept and Myriad Genetics are among the companies on the list. The report indicates that in 2017, more than 40 companies are active in the global market for liquid biopsy diagnostic and monitoring tests. These are detailed in the report, The Worldwide Market for Liquid Biopsy, the first major study to look at the market and define competitor performance and market sizing from an independent, healthcare specialist market research firm.
Liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.
"Up to the present, several liquid biopsy diagnostic tests have been developed based on these technologies, and are currently commercialized for different types of cancers and applications," said Bruce Carlson, Publisher of Kalorama Information.
Although in its early stages of development, the overall market is a dynamic and fast-developing one that is expected to evolve into a billion-dollar market by 2021. Geographically, the market participants are concentrated in the USA and Europe, with several competitors based also in Asia. The liquid biopsy market is largely driven by technological innovation and high demand for non-invasive cancer diagnostic and monitoring tests, and focused thus far to a large extent on the development of tests for available clinically-actionable molecular targets and approved therapies. Another area of strong interest in this market is the development of tests for the diagnosis of cancer at earlier stages, when patients suffering from this disease have greater treatment options and chances of survival. These driving forces are expected to continue to exert a major influence on the evolution of this market during the forecast period of this study.
The participating companies offer a variety of liquid biopsy diagnostic and monitoring solutions based on a variety of technological approaches, such as the isolation and analysis of ctDNA, CTCs and extracellular vesicles.
"Given the advantages of isolating and analyzing ctDNA compared to CTCs and other analytes, along with the lower barriers to entry in this segment, the ctDNA-based liquid biopsy tests market segment is the most active one, with many competitors engaged in the development and commercialization of such tests," said Adriana Rusu, biotechnology and IVD market analyst and the report's author.
The overall market competitiveness increased in recent years as a result of new product introductions, and is projected to continue to increase within the next five years, as many companies are developing new products that are expected to reach the market in the near future. The market growth will be influenced by factors such as the rising incidence and prevalence of cancer at the global level, increasing use of personalized medicine, regulatory hurdles, reimbursement considerations, and adoption and integration issues of these.
Kalorama Information's Report The Worldwide Market for Liquid Biopsy (by Analyte [ctDNA, cfDNA, Other], by Application - Screening/Drug Monitoring/Diagnostic, by Region [US, Europe, Asia, ROW] and by Type of Cancer) is available at: https://www.kaloramainformation.com/prod-toc/Worldwide-Liquid-Biopsy-Analyte-ctDNA-cfDNA-Application-Screening-Drug-Monitoring-Diagnostic-Region-Europe-Asia-ROW-Type-Cancer-10975987/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.
Press Contact:
Bruce Carlson
212 807 2262
[email protected]
SOURCE Kalorama Information
Share this article